European Pharmaceutical Review

OCTOBER 19, 2022

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 26 April, 2016.

Food and Drug Administration 96

Food and Drug Administration Pharmaceutical products Pharmaceutical FDA 96

pharmaphorum

JULY 27, 2022

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

Government 92

Government Recruitment Medicine Patients 92

European Pharmaceutical Review

JUNE 24, 2022

This means numerous key aspects of how pharmaceuticals are regulated in the EU could be affected, from costing and reimbursement to intellectual property rights, incentives and more. Stakeholders in the EU often use the risk-adjusted Net Present Value (rNPV) investment model to determine whether to invest in a pharmaceutical product.

Pharmaceutical 105

Pharmaceutical Medicine Marketing Competition 105

PharmaKinnex

AUGUST 23, 2022

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. Let’s dive into the current state of the pharma industry and learn more about what your team can do to stay ahead of the curve and the competition. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

Pharma 52

Pharma Sales Sales Strategy Marketing 52